In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
about
Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infectionInterleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell culturesUntil Death Do Us Part: Necrosis and Oxidation Promote the Tumor MicroenvironmentStoichiometry based steady-state hepatic flux analysis: computational and experimental aspects.Hormones and the immune response.Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndromeAntibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatmentIncreased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.Systemic immunological effects of cytokine genes injected into skeletal muscle.Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test CombinationBasophils are the major producers of IL-4 during primary helminth infection.Motility and ultrastructure of large granular lymphocytes on lipid bilayers reconstituted with adhesion receptors LFA-1, ICAM-1, and two isoforms of LFA-3.Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing?Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation.Anterior pituitary hormone control by interleukin 2.Gene therapy: a potential approach for cancer pain.Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.Clinical and immunological effects of single bolus administration of recombinant interleukin-2 in cattle.Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.A Case of Myocarditis and Near-Lethal Arrhythmia Associated With Interleukin-2 Therapy.Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy.Immunotherapies: Exploiting the Immune System for Cancer Treatment.
P2860
Q24531350-9101FFA0-E5C4-42F1-A152-CCE980A16D9FQ24564695-8248CEA2-6B1E-4710-95F6-28BD1A5A1943Q26745898-CC312A70-063C-4165-89A4-C0E3099CC073Q30437950-DCE4CA88-2FE7-4D1F-8401-39B2B4CB0E84Q33561339-9C4623CB-A575-4807-AA98-8C7015967612Q33811204-7EF9EA69-AAD2-450D-BE22-2B00138DF84AQ34565648-E3931D35-7D2B-4625-B00F-C4561CEB1EA1Q35163167-6A1033FA-45AC-49B3-94A9-9181BD31FD61Q35657649-07DB0E7E-93C2-4438-960A-C84B15ACACB3Q36081509-4760FEA8-1E86-4032-9B67-8A8BAACF8293Q36302958-2B219852-0550-4D64-AAB5-B7535F778C24Q36305283-586BD461-68FC-4497-95C0-848CED688006Q36370697-5DD9F096-E52D-4506-B87D-024251AE2744Q36530484-3B11817A-D5AD-4D97-8824-5F6E53766F0DQ36989234-756E70DA-FB4D-4A5C-A9D0-A2401B215AA6Q37137406-29D2AAE9-E7A8-4DD3-AA11-5A27B1E4A3B4Q37470571-EE5526EF-B215-455C-801A-CD648C415967Q38745962-17C1B0CA-0CBC-424C-BBBB-4271C04DA653Q41657844-92B36377-2CA6-413D-A893-D18102494A0FQ41706967-C466F59E-3342-44E7-9B27-A61895CAA3E3Q42585683-3A5E1BBD-9494-4780-9D24-AECF155F4DF2Q45833763-61F7F162-9F5D-41FB-BEF4-25B27AF3FEBEQ49332278-A04258A9-D69D-4EBE-9003-1CCEC21E2856Q54421785-BC22B287-C866-45C0-94DD-CEDC5AB5D2F2Q55258552-3CE151F4-E7CB-47AF-9F33-691D56F118B1Q55362851-98EB7B0A-A4B1-4AC9-9161-9DC246B538A1
P2860
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
In vivo administration of puri ...... ll line-derived interleukin 2.
@en
type
label
In vivo administration of puri ...... ll line-derived interleukin 2.
@en
prefLabel
In vivo administration of puri ...... ll line-derived interleukin 2.
@en
P2093
P1476
In vivo administration of puri ...... ll line-derived interleukin 2.
@en
P2093
P304
P407
P577
1985-01-01T00:00:00Z